Vol 9, No 5 (2020)
Review article
Published online: 2020-11-10
New Onset Diabetes After Transplantation (NODAT) — scientific data review
DOI: 10.5603/DK.2020.0047
Clin Diabetol 2020;9(5):356-366.
Abstract
New onset diabetes after transplantation (NODAT) is one of the most common and serious complications of solid organ transplantation. The incidence of NODAT is estimated to range from 2% to 53%. Patients who develop new onset diabetes after transplantation are significantly more frequently exposed to a higher risk of death and cardiovascular incidents as well as other adverse effects, such as decreased patient survival, higher infection rates and early graft loss. Identifying high-risk patients, undertaking preventive action and applying appropriate treatment can limit the development of new onset diabetes after transplantation and improve a patient’s long-term prognosis.
Keywords: new onset diabetes after transplantationrisk factorsdiagnosticstreatment
References
- Rodrigo E, Fernández-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol. 2006; 17(12 Suppl 3): S291–S295.
- Milczarek M, Wojciechowska M, Mamcarz A, et al. Waskulopatia w przeszczepionym sercu — nowe trendy w diagnostyce i leczeniu. Folia Cardiologica. 2017; 12(1): 50–54.
- Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009; 4(4): 853–859.
- Bergrem HA, Valderhaug TG, Hartmann A, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol. 2010; 5(4): 616–622.
- Sharif A, Hecking M, de Vries APJ, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014; 14(9): 1992–2000.
- Hecking M, Werzowa J, Haidinger M, et al. European-New-Onset Diabetes After Transplantation Working Group. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant. 2013; 28(3): 550–566.
- Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008; 3 Suppl 2: S38–S48.
- Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7): 539–553, doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
- Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2019; 8(1): 1–95.
- Armstrong KA, Prins JB, Beller EM, et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol. 2006; 1(1): 100–108.
- Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant. 2011; 25(6): 885–891.
- Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002; 25(3): 583–592.
- Hjelmesaeth J, Midtvedt K, Jenssen T, et al. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care. 2001; 24(12): 2121–2126.
- Sharif A, Cohney S. Post-transplantation diabetes—state of the art. The Lancet Diabetes & Endocrinology. 2016; 4(4): 337–349.
- Hjelmesaeth J, Asberg A, Müller F, et al. New-onset posttransplantation diabetes mellitus: insulin resistance or insulinopenia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection. Curr Diabetes Rev. 2005; 1(1): 1–10.
- Pham PTT, Pham PMT, Pham SV, et al. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes. 2011; 4: 175–186.
- Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation. 2010; 89(12): 1526–1532.
- Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003; 3(2): 178–185.
- Dedinská I, Graňák K, Vnučák M, et al. Role of sex in post-transplant diabetes mellitus development: Are men and women equal? J Diabetes Complications. 2019; 33(4): 315–322.
- Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors. Transplantation. 1991; 51(2): 343–347.
- Martínez-Castelao A, Hernández MD, Pascual J, et al. investigators of the HIGLU study. Detection and treatment of post kidney transplant hyperglycemia: a Spanish multicenter cross-sectional study. Transplant Proc. 2005; 37(9): 3813–3816.
- Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001; 72(6): 1066–1072.
- Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia. 2004; 47(9): 1550–1556.
- Hjelmesaeth J, Müller F, Jenssen T, et al. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant. 2005; 20(11): 2311–2315.
- Schweer T, Gwinner W, Scheffner I, et al. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation. Clin Transplant. 2014; 28(4): 512–519.
- Numakura K, Satoh S, Tsuchiya N, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation. 2005; 80(10): 1419–1424.
- Gourishankar S, Jhangri GS, Tonelli M, et al. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant. 2004; 4(11): 1876–1882.
- Yates CJ, Barraclough KA, McWhinney BC, et al. A practical limited sampling strategy to predict free prednisolone exposure and glycemia in kidney transplant recipients. Ther Drug Monit. 2014; 36(1): 18–23.
- Cieniawski D, Miarka P, Jaśkowski P, et al. Cukrzyca potransplantacyjna — trudności w diagnostyce i rozpoznaniu. Varia Medica. 2018; 61873: 446–449.
- Alebiosu OC, Ayodele OE. Natural history and epidemiology of post transplantation diabetes mellitus. Afr Health Sci. 2005; 5(3): 255–260.
- Vincenti F, Friman S, Scheuermann E, et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007; 7(6): 1506–1514.
- Prasad GV, Kim SJ, Huang M, et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). Am J Transplant. 2004; 4(11): 1897–1903.
- Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011; 11(8): 1633–1644.
- Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008; 19(7): 1411–1418.
- Durlik M, Polskie Towarzystwo Transplantacyjne, Zalecenia dotyczące leczenia immunosupresyjnego po przeszczepieniu narządów unaczynionych, 2014.
- Vest LS, Koraishy FM, Zhang Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant. 2018; 32(8): e13302.
- Palepu S, Prasad GV. New-onset diabetes mellitus after kidney transplantation: Current status and future directions. World J Diabetes. 2015; 6(3): 445–455.
- Balas B, Belfort R, Harrison SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol. 2007; 47(4): 565–570.
- Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010; 95(2): 592–600.
- Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ. 2012; 345: e4541.
- Cehic MG, Nundall N, Greenfield JR, et al. Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. J Transplant. 2018; 2018: 1025893.
- Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014; 2014: 617638.
- Amin M, Suksomboon N. Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions. Drug Saf. 2014; 37(11): 903–919.
- Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. 2013; 61(4): 579–587.
- Ravassa S, Zudaire A, Díez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res. 2012; 94(2): 316–323.
- Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14): 1317–1326.
- White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14): 1327–1335.
- Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3): 232–242.
- Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
- Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011; 6(1): 9–20.